Stock at all time Low!?!


anonymous

Guest
Bayer’s stock has taken a nosedive, now hovering around the $5 mark—marking a 20-year low! During the recent earnings call, investors vented their frustrations, demanding to know why there’s no clear mid-term strategy in sight. It raises an intriguing question: why are skilled professionals still sticking around this tumultuous ride?

Let’s be real—claiming that Nubeqa and Kerendia are exceeding expectations seems almost comical when you consider that only a third of our sales team qualifies for bonuses. With Nubeqa facing a coverage loss in Medicare Part D next year and uncertainty looming over a lifestyle menopause drug, it’s challenging to spot a silver lining!

The big question now looms: how low will the stock sink before we witness job cuts and asset sell-offs as the company struggles to stay afloat? Before anyone from management jumps in to dismiss these concerns or suggests I find a new job, let me assure you—all talented individuals already have or are looking. The reality is, those who remain might just be too complacent, underperforming, or financially comfortable to make a move.
 


Bayer’s stock has taken a nosedive, now hovering around the $5 mark—marking a 20-year low! During the recent earnings call, investors vented their frustrations, demanding to know why there’s no clear mid-term strategy in sight. It raises an intriguing question: why are skilled professionals still sticking around this tumultuous ride?

Let’s be real—claiming that Nubeqa and Kerendia are exceeding expectations seems almost comical when you consider that only a third of our sales team qualifies for bonuses. With Nubeqa facing a coverage loss in Medicare Part D next year and uncertainty looming over a lifestyle menopause drug, it’s challenging to spot a silver lining!

The big question now looms: how low will the stock sink before we witness job cuts and asset sell-offs as the company struggles to stay afloat? Before anyone from management jumps in to dismiss these concerns or suggests I find a new job, let me assure you—all talented individuals already have or are looking. The reality is, those who remain might just be too complacent, underperforming, or financially comfortable to make a move.
How low can you go, how low can you go! Its a race to the bottom!
 






Bayer’s stock has taken a nosedive, now hovering around the $5 mark—marking a 20-year low! During the recent earnings call, investors vented their frustrations, demanding to know why there’s no clear mid-term strategy in sight. It raises an intriguing question: why are skilled professionals still sticking around this tumultuous ride?

Let’s be real—claiming that Nubeqa and Kerendia are exceeding expectations seems almost comical when you consider that only a third of our sales team qualifies for bonuses. With Nubeqa facing a coverage loss in Medicare Part D next year and uncertainty looming over a lifestyle menopause drug, it’s challenging to spot a silver lining!

The big question now looms: how low will the stock sink before we witness job cuts and asset sell-offs as the company struggles to stay afloat? Before anyone from management jumps in to dismiss these concerns or suggests I find a new job, let me assure you—all talented individuals already have or are looking. The reality is, those who remain might just be too complacent, underperforming, or financially comfortable to make a move.
Well put! You nailed it…
 


Bayer’s stock has taken a nosedive, now hovering around the $5 mark—marking a 20-year low! During the recent earnings call, investors vented their frustrations, demanding to know why there’s no clear mid-term strategy in sight. It raises an intriguing question: why are skilled professionals still sticking around this tumultuous ride?

Let’s be real—claiming that Nubeqa and Kerendia are exceeding expectations seems almost comical when you consider that only a third of our sales team qualifies for bonuses. With Nubeqa facing a coverage loss in Medicare Part D next year and uncertainty looming over a lifestyle menopause drug, it’s challenging to spot a silver lining!

The big question now looms: how low will the stock sink before we witness job cuts and asset sell-offs as the company struggles to stay afloat? Before anyone from management jumps in to dismiss these concerns or suggests I find a new job, let me assure you—all talented individuals already have or are looking. The reality is, those who remain might just be too complacent, underperforming, or financially comfortable to make a move.
It’s a big mistake if anybody is working here with one eye on the stock. It will not recover in your career lifetime.
 


It’s a big mistake if anybody is working here with one eye on the stock. It will not recover in your career lifetime.
How do we know it's bad? The silence from Bayer management is telling. Those engagement surveys are nothing more than a superficial façade for the culture they want to make believe is real, aimed at appeasing their own PMP’s. If things were genuinely okay, management would actively address these concerns, yet many employees at all levels are preparing to leave. The prevailing sentiment is clear: I’m done speaking up because it leads to no change! The phrase DSO perfectly captures the mood: Done being Screwed Over! Keep your expanded company car selector and let me have an actual shot and earning a real bonus! Another ploy when they tell us later this year its another year of shitty bonuses!!!
 


Bayer’s stock has taken a nosedive, now hovering around the $5 mark—marking a 20-year low! During the recent earnings call, investors vented their frustrations, demanding to know why there’s no clear mid-term strategy in sight. It raises an intriguing question: why are skilled professionals still sticking around this tumultuous ride?

Let’s be real—claiming that Nubeqa and Kerendia are exceeding expectations seems almost comical when you consider that only a third of our sales team qualifies for bonuses. With Nubeqa facing a coverage loss in Medicare Part D next year and uncertainty looming over a lifestyle menopause drug, it’s challenging to spot a silver lining!

The big question now looms: how low will the stock sink before we witness job cuts and asset sell-offs as the company struggles to stay afloat? Before anyone from management jumps in to dismiss these concerns or suggests I find a new job, let me assure you—all talented individuals already have or are looking. The reality is, those who remain might just be too complacent, underperforming, or financially comfortable to make a move.
The stock is now in the $4 range! How much further does it need to drop before the realization hits that the current strategy is failing? Divestment or a leadership change are the only viable options at this point, and the investor community is growing increasingly impatient with the ongoing lack of progress! Its delusional to think this will turn around.
 


The stock is now in the $4 range! How much further does it need to drop before the realization hits that the current strategy is failing? Divestment or a leadership change are the only viable options at this point, and the investor community is growing increasingly impatient with the ongoing lack of progress! Its delusional to think this will turn around.
High of $5.05 today for a company as large as ours and been around as long. BA you stupid idiot. You e ruined this company’. We are on a downward spiral.
 


High of $5.05 today for a company as large as ours and been around as long. BA you stupid idiot. You e ruined this company’. We are on a downward spiral.
Oh wait back down to 5.03 well done Bill really doing a stellar job turning this ship around. cannot wait to see my bonus! Im sure YOURS though is gonna be larger than ever. Pat yourself on the back for doing such a great job wronging this right.
 








It’s only a matter of time before we see more layoffs and budget cuts! Leadership has failed to grow the top line due to misguided strategies, resulting in cuts to the bottom line—and to our people. Clearly, this approach isn’t working either. Real change is necessary at the top levels of US Pharma leadership if we want to see a turnaround. It’s imperative that we replace the Executive Leaders in Sales, Marketing, and Market Access. If not, we’ll witness our stock price slip to below $4.00, and eventually to $3.00.
 


It’s only a matter of time before we see more layoffs and budget cuts! Leadership has failed to grow the top line due to misguided strategies, resulting in cuts to the bottom line—and to our people. Clearly, this approach isn’t working either. Real change is necessary at the top levels of US Pharma leadership if we want to see a turnaround. It’s imperative that we replace the Executive Leaders in Sales, Marketing, and Market Access. If not, we’ll witness our stock price slip to below $4.00, and eventually to $3.00.
 




It’s only a matter of time before we see more layoffs and budget cuts! Leadership has failed to grow the top line due to misguided strategies, resulting in cuts to the bottom line—and to our people. Clearly, this approach isn’t working either. Real change is necessary at the top levels of US Pharma leadership if we want to see a turnaround. It’s imperative that we replace the Executive Leaders in Sales, Marketing, and Market Access. If not, we’ll witness our stock price slip to below $4.00, and eventually to $3.00.
That would require that boys club to have some self awareness and make some cuts to their buddies. Which will never happen then want to sink thus boat together I guess so pathetic
 









Write your reply...